[ad_1]
Altos Labs was set up with a lot of startup funding for each science, a team full of Nobel Prize winners – and high hopes that it is trying to overcome death.
But the top scientists who started the new business, which last week revealed it raised $ 3bn from investors, are insisting they are planning to change the disease so that people can stay healthy longer instead of chasing the sci-fi vision to help others live forever.
Rick Klausner, chief science and former director of the US National Cancer Institute, told the Financial Times that the company wants to be a “Bell Labs” for biology, meaning part of the research and development behind technologies as a transistor.
High Labs will explore how to regenerate cells under stress including genetic disorders, injuries or aging. By regenerating cells, it is able to find drugs that cure many diseases at the same time, which can disrupt the pharmaceutical business.
Klausner said the first scientific papers on the revival cells were received with “great skepticism”, meaning that “it was too good to be true.” But he added that the findings were also downgraded by many other labs and in some cases, and have been relatively stable.
Altos Labs kept its job a secret until last week when it revealed its huge sums of money from unnamed individuals and announced it had assassinated GlaxoSmithKline senior scientist. Hal Barron being a great senior.
Preliminary reports also said that their sponsors include billionaires Jeff Bezos and Yuri Milner, and they think this would be very recent for startup groups trying to use new anti-aging technology. extend life.
However, Hans Bishop, Altos’ new president who worked with Klausner on the origins of oncology including Grail and Juno Therapeutics, said his goal was to promote “health”, and that any increase in longevity could be “dangerous consequences”.
He stated that while cancer treatment may only extend the life span of most people, the effects will be far-reaching.
“Our aim is to focus on this long-standing issue that people have been facing for decades because of the devastating effects of chronic illness. . . yields and income are the most devastating effects of human activity, “he said.
Altos Labs will operate from two hubs in California and one in Cambridge in the UK, with an important study conducted in Japan, where Nobel Prize winner Shinya Yamanaka launched a revitalization program. Yamanaka will oversee research in Japan and serve as a consultant, while Nobel laureates Jennifer Doudna, Frances Arnold and David Baltimore will join the organization.
The company seeks to integrate advanced scientists from higher education with the goal of developing drugs, although much research is still limited to mice.
Klausner, who came up with the first idea at several video conferences in 2020, said the company realized it could go into more clinical trials than expected.
“I think we can get into the people as quickly as we can,” he said.
[ad_2]
Source link
